"Leaky Gut" as a Keystone of the Connection between Depression and Obstructive Sleep Apnea Syndrome? A Rationale and Study Design

• Published in: Metabolites Vol. 12; no. 2; p. 152
• Main Authors: Gawlik-Kotelnicka, Oliwia, Margulska, Aleksandra, Gabryelska, Agata, Sochal, Marcin, Białasiewicz, Piotr, Strzelecki, Dominik
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 06.02.2022; MDPI
• Subjects: Antioxidants; Apnea; Biomarkers; Body mass index; Comorbidity; depression; Enzyme-linked immunosorbent assay; Fatty acids; Inflammation; Interleukin 6; intestinal permeability; Intestine; Malondialdehyde; Mental depression; Microbiota; Obesity; obstructive sleep apnea; Oxidative stress; Patients; Permeability; Population studies; Probiotics; Sleep; Sleep apnea; Sleep disorders; Study Protocol; Therapeutic applications; Transplantation; Tumor necrosis factor; Tumors; obstructive sleep apnea; intestinal permeability; depression; inflammation; oxidative stress
• ISSN: 2218-1989; 2218-1989
• DOI: 10.3390/metabo12020152

Obstructive sleep apnea (OSA) and depression are highly comorbid. Immune alterations, oxidative stress or microbiota dysfunction have been proposed as some mechanisms underlying this association. The aim of the proposed study is to assess the severity and profile of OSA and depressive symptoms in the context of serum microbiota metabolites, biomarkers of intestinal permeability, inflammation and oxidative stress in adult patients diagnosed with OSA syndrome. The study population consists of 200 subjects. An apnoea-hypopnoea index ≥ 5/hour is used for the diagnosis. Depressive symptoms are assessed with Beck Depression Inventory. Measured serum markers are: tumour necrosis factor-alpha and interleukin-6 for inflammation, total antioxidant capacity and malondialdehyde concentration for oxidative stress, zonulin, calprotectin, lipopolisaccharide-binding protein and intestinal fatty acids-binding protein for intestinal permeability. All of the above will be measured by enzyme-linked immunosorbent assay (ELISA). Associations between clinical symptoms profile and severity and the above markers levels will be tested. It would be valuable to seek for overlap indicators of depression and OSA to create this endophenotype possible biomarkers and form new prophylactic or therapeutic methods. The results may be useful to establish a subpopulation of patients sensitive to microbiota therapeutic interventions (probiotics, prebiotics, and microbiota transplantation).